# Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)

> **NCT03850964** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Cure HHT** · enrollment: 70 (estimated)

## Conditions studied

- Hereditary Hemorrhagic Telangiectasia
- Epistaxis
- Anemia
- Nosebleed
- HHT

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03850964
- **Lead sponsor:** Cure HHT
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-08
- **Primary completion:** 2025-11-21
- **Final completion:** 2026-07
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03850964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03850964, "Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03850964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*